More Than 85 Small Molecule Protein Degraders Are Currently Being Evaluated For The Treatment Of Various Disease Indications; In Addition, There Are Over 25 Technology Platforms Available For Use In Therapy Development Efforts

>

More than 85 small molecule protein degraders are currently being evaluated for the treatment of various disease indications; in addition, there are over 25 technology platforms available for use in therapy development efforts

The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. The first targeted protein degrader, called proteolysis targeting chimera (PROTAC), was developed about a decade ago. Presently, a variety of other such chemical entities and molecular glues are under investigation. In fact, certain pipeline candidates are already in the mid to late-phase trials and are anticipated to soon enter the market.

 

To order this 330+ page report, which features 130+ figures and 145+ tables, please visit this link

 

The USD 3.6 billion (by 2030) financial opportunity within the target protein degradation market has been analyzed across the following segments:

  • Type of payment of licensing agreements
  • Upfront payments
  • Milestone payments

 

  • Type of protein degrader
  • Degronimids
  • PROTACs
  • SARDs / SERDs
  • Specific BET and DUB inhibitors
  • Other protein degraders

 

  • Therapeutic area
  • Neurodegenerative disorders
  • Oncological disorders
  • Other therapeutic areas

 

  • Route of administration
  • Oral
  • Intravenous
  • Other routes

 

  • Key geographical region
  • North America
  • Europe
  • Asia-Pacific

 

The Targeted Protein Degradation Market: Focus on Therapeutics and Technology Platforms (based on Degronimids, ENDTACs, Epichaperome Inhibitors, Hydrophobic Tags, IMiDs, LYTACs, Molecular Glues, PHOTACs, PROTACs, Protein Homeostatic Modulators, SARDs, SERDs, SNIPERs, and Specific BET and DUB Inhibitors), 2020-2030 report features the following companies, which we identified to be key players in this domain:

  • Arvinas
  • Captor Therapeutics
  • Celgene
  • Genetech
  • Kymera Therapeutics
  • Mission Therapeutics
  • Progenra
  • Radius Health
  • Sanofi Genzyme
  • Zenopharm

 

Table of Contents

 

  1. Preface

  2. Executive Summary

  3. Introduction

  4. Current Market Landscape

  5. Company Profiles

  6. Clinical Trial Analysis

  7. KOL Analysis

  8. Publication Analysis

  9. Funding and Investment Analysis

  10. Partnerships and Collaborations

  11. Market Sizing and Opportunity Analysis

  12. Executive Insights

 

  1. Concluding Remarks

 

  1. Appendix 1: Tabulated Data

 

  1. Appendix 2: List of Companies and Organizations

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/protein-degradation-market/289.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

gaurav.chaudhary@rootsanalysis.com

 

 

Share:

Keywords: degraders,disease indications,pharma,health & caare,pharmaceutical,active pharmaceutical ingredient,pharmaceutical product development inc

Comments

Other related blogs

Buy Abortion Pills Online Usa and Rid from Unwanted Pregnancy

By : Safematernology

Medical abortion is the procedure that is conducted with the use of termination pills, which does no..


The gene therapy market is estimated to be worth USD 11.6 billion in 2030, predicts Roots Analysis

By : Roots Analysis

  With multiple approved products, the field of gene therapies has gained substantial momentum..


The gene therapy market is projected to grow at an annualized rate of 45%, till 2030

By : Roots Analysis

Roots Analysis has done a detailed study on Gene Therapy Market (3rd Edition), 2019-2030, covering k..


The global digital therapeutics market is projected to be worth over USD 8.86 billion by 2030

By : Roots Analysis

Recent advances in information technology and biomedical science have enabled the development of a n..